Immunotherapy and Chemotherapy for Stage III Colon Cancer
Author Information
Author(s): Baars A, Claessen A M E, Wagstaff J, Giaccone G, Scheper R J, Meijer S, Schakel M J A G, Gall H E, Meijer C J L M, Vermorken J B, Pinedo H M, van den Eertwegh A J M
Primary Institution: Vrije Universiteit Medical Center, Amsterdam, The Netherlands
Hypothesis
Can combining active specific immunotherapy with chemotherapy improve outcomes for stage III colon cancer patients?
Conclusion
The study found that the anti-tumor immune response from immunotherapy is only minimally affected by chemotherapy, and the combined treatment does not cause unexpected toxicity.
Supporting Evidence
- The study showed that the size of delayed type hypersensitivity reactions was only minimally affected by chemotherapy.
- 30% of patients experienced grade III or IV toxicity, which is comparable to standard chemotherapy alone.
- The median follow-up time for patients was 21.7 months.
Takeaway
Doctors tested a new treatment for colon cancer that combines vaccines with chemotherapy, and they found it mostly safe and effective.
Methodology
The study involved 56 patients receiving a combination of active specific immunotherapy and chemotherapy, with measurements of immune response and toxicity.
Potential Biases
Potential bias due to the study being conducted at a single institution and the exclusion of certain patient groups.
Limitations
The study's sample size was relatively small, and the results may not be generalizable to all stage III colon cancer patients.
Participant Demographics
Patients with stage III colon cancer, excluding those with distant metastases or other significant health issues.
Statistical Information
P-Value
0.01
Statistical Significance
p=0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website